Working at the intersection of innovation, technology and 产品介绍 development, I manage the external innovation 文件夹 for antibody discovery and protein engineering in R&D. This includes identifying novel technologies for our core therapeutic areas, as well as emerging platforms like cell therapy, peptide delivery, oral biologics and adeno associated virus (AAV), and building next generation antibody conjugate technologies for tissue targeting and to prevent off target toxicity.

My role sees me liaise closely with our therapeutic area heads and business development colleagues to lead and execute the evaluation of novel technologies through data-driven feasibility studies. I also design and run open innovation challenges and scientific advisory boards to ensure we address internal gaps and identify the most exciting technologies and collaborators.

With over 20 years of experience in pharma/biotech, I started my career as a research scientist in academia after gaining my PhD from Purdue University in Chemistry and Materials Science & Engineering.

Over my career, I have led 团队s to secure a number of novel drug delivery approvals such as an injectable biologic drug-device combination 产品介绍, an active transdermal patch and a dry powder inhalation device. I also have 更多 than 25 peer reviewed publications and 2 book chapters, as well as several granted patents.


永利皇冠游戏网站

皇冠官网手机版

皇冠官网手机版

2017: Global excellence award for the best patent 皇冠官网手机版


永利皇冠登录

皇冠官网手机版

皇冠官网手机版

2013: Exceptional Team Performance award皇冠官网手机版



皇冠官网入口

CURRENT ROLE

永利皇冠

2017-19

永利皇冠

2019

永利皇冠

2014-2017

永利皇冠

永利皇冠

Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.皇冠官网手机版

Tyagi P, Subramony JAJ Controlled Release, 2018. 272; 159–168.

Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer.皇冠官网手机版

Chen F, et alNature Comms 2018. 9:4141

Oral peptide delivery: Translational challenges due to physiological effects.皇冠官网手机版

Tyagi P, Pechenov S, Subramony JA. J Controlled Release. 2018. 287; 167–176

Improving Drug-Like Properties of Insulin and GLP-1 via Molecule Design and Formulation and Improving Diabetes Management with Device & Drug Delivery.皇冠官网手机版

Pechenov S, Bhattacharjee H, Yin D, Mittal S, Subramony JAAdv Drug Deliv Rev. 2017.

Engineered in-situ depot-forming hydrogels for intratumoral drug delivery.皇冠官网手机版

Fakhari A, Subramony JA. J Controlled Release 2015. 220; 465–475

Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large Volume Protein Delivery.皇冠官网手机版

Doughty DV, Clawson CZ, Lambert W, Subramony JAJ Pharm Sci. 2016 105(7):2105-13